Trial Profile
An Open-Label, Multiple Simon 2-Stage Study of Itacitinib Administered Orally to Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) or Post Essential Thrombocythemia Myelofibrosis (PET-MF)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Sep 2021
Price :
$35
*
At a glance
- Drugs Itacitinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Therapeutic Use
- Acronyms RESET
- Sponsors Incyte Corporation
- 25 Aug 2021 Status changed from active, no longer recruiting to completed.
- 07 Jul 2021 Planned End Date changed from 31 May 2021 to 31 Dec 2021.
- 08 Apr 2021 Planned End Date changed from 1 Mar 2021 to 31 May 2021.